Hans Kragten

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker et al. · The Lancet · 2020 · 723 citations · Full text

Heart Failure, Iron Metabolism, Clinical Nutrition +5

Discrimination Between Myocardial and Skeletal Muscle Injury by Assessment of the Plasma Ratio of Myoglobin Over Fatty Acid–Binding Protein

Frans A. van Nieuwenhoven, Appie H. Kleine, K. W. H. Wodzig et al. · Circulation · 1995 · 222 citations · Full text

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Ewa A. Jankowska, Bridget‐Anne Kirwan, Mikhail Kosiborod et al. · European Heart Journal · 2021 · 102 citations · Full text

Does lowering of cholesterol levels influence functional properties of large arteries?

Mirian J. Kool, Harry Struijker Boudier, Lucas Van Bortel et al. · European Journal of Clinical Pharmacology · 1995 · 65 citations

Hypertension, Vascular Disease, Functional Properties +10

Rationale and Design of the AFFIRM-AHF Trial: A Randomised, Double-Blind, Placebo-Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron-Deficient Patients Admitted for Acute Heart Failure

Piotr Ponikowski, Bridget‐Anne Kirwan, Stefan D. Anker et al. · European Journal of Heart Failure · 2019 · 53 citations · Full text